Research programme: immunotherapeutics - MacroGenics

Drug Profile

Research programme: immunotherapeutics - MacroGenics

Latest Information Update: 12 Nov 2008

Price : $50

At a glance

  • Originator MacroGenics
  • Class Monoclonal antibodies; Viral vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Infections
  • Discontinued Autoimmune disorders; Cancer

Most Recent Events

  • 04 Feb 2008 Preclinical development for infectious diseases is ongoing
  • 07 Jun 2002 Preclinical trials in Infections in USA (unspecified route)
  • 07 Jun 2002 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top